About Us

About Us

Eventide Asset Management, LLC is a Boston-based Registered Investment Advisor and serves as the Advisor to Eventide Mutual Funds. Founded in 2008 with a vision to provide high performance values-based investments for individuals, financial advisors, and institutions, Eventide has become a leader in faith-based and socially responsible investing. Eventide is the Advisor to the Eventide Gilead Fund, the Eventide Healthcare & Life Sciences Fund, and the Eventide Multi-Asset Income Fund, and manages more than $1.8 billion in net assets.

We believe high-quality companies where we have a differentiated view from the market and that trade at a discount to intrinsic value offer superior long-term risk-adjusted returns.

Sales and Marketing

Jason Myhre

Director of Marketing & Advisory Services, Managing Partner

Jason Myhre serves as the Director of Marketing and Advisory Services for Eventide. He is responsible for Eventide’s internal support and service to advisory relationships, overseeing Eventide’s Advisory Services team, including the Product Specialist team.

Prior to Eventide, Mr. Myhre worked in internal sales and managed key customer relationships for Altec. He holds a master’s and bachelor’s degree from the University of Florida, and studied architecture at Harvard’s Graduate School of Design.

Jeff Cave, CIMA®

Director of Distribution

Jeff Cave serves as the Director of Distribution for Eventide. He is responsible for external sales and distribution.

Prior to joining Eventide in 2015, Mr. Cave was with Merrill Lynch for almost 23 years, most recently as Director, Ultra High Net Worth Wealth Management Specialist for the Private Banking and Investment Group at Merrill Lynch, based in New York City. Mr. Cave holds the Certified Investment Management Analyst certification, administered by Investment Management Consultants Association and taught in conjunction with the Wharton School at the University of Pennsylvania. He is a Qualified Kingdom Advisor and member of the Board of Kingdom Advisors and the Board of Managers for the Ron Blue Institute for Financial Planning.

He holds an MBA from the University of Minnesota and a BBA in Management and Marketing from Loyola University.

Harry Nelson, CIMA®

Director of Institutional Markets

Harry Nelson serves as the Director of Institutional Markets for Eventide. He is responsible for institutional sales and key account relationships.

Prior to joining Eventide in 2017, Harry was President of GuideStone Capital Management, LLC. Before that, Mr. Nelson served in business development roles at GuideStone and Golden Capital Management. Harry holds the Certified Investment Management Analyst certification, administered by Investment Management Consultants Association and taught in conjunction with the Wharton School of Business at the University of Pennsylvania.

He earned his B.A. in Political Science from The Citadel.

Rob Moll

Director of Communications & Advocacy

Rob Moll serves as Eventide’s Director of Communications and Advocacy, helping to shape and share Eventide's mission of values-based investing.

Prior to joining Eventide, Rob was communications officer to the president at World Vision, a global Christian humanitarian organization. Rob is editor at large for Christianity Today magazine and the author of two books. His writing has appeared in The Wall Street Journal, The Washington Post, TIME, Forbes.com, and numerous other publications. Members of the media can contact Rob for interviews and information.

Tim Weinhold

Director of Faith & Business

Tim Weinhold serves as Director of Faith and Business for Eventide Funds, and has served in a faith-and-business/investing-thought-leadership capacity with Eventide since its founding.

He is also a Fellow of the Center for Enterprise, Markets and Ethics (CEME) at Oxford. In addition, Tim is an adjunct faculty member of the School of Business, Government and Economics at Seattle Pacific University and serves on the school’s Executive Advisory Board. Tim co-founded four entrepreneurial ventures, including a VC-funded computer graphics company, and for several years provided real estate consulting to major corporations. Tim is passionate about, and a long-time student of, 'business for blessing,' i.e., a deeply biblical understanding of God's intent for the purpose and practice of business. He holds a bachelor’s degree with honors from Harvard University.

Portfolio Managers

Finny Kuruvilla, MD, PhD

Chief Investment Officer, Portfolio Manager, Managing Partner

Finny Kuruvilla serves as the CIO for Eventide Funds, lead Portfolio Manager on the Eventide Gilead Fund, and Portfolio Manager on the Eventide Healthcare & Life Sciences Fund.

Dr. Kuruvilla has a unique background in healthcare, statistics, and investing. Concurrent with Eventide, from 2008 through 2016, he was a Principal at Clarus Ventures, a leading healthcare and life sciences venture capital firm. Prior to joining Eventide, from 2006-2008, Dr. Kuruvilla was a research fellow at the Broad Institute of Harvard and MIT, and from 2005-2008, Dr. Kuruvilla was a clinical fellow at the Brigham and Women’s Hospital and Children’s Hospital Boston and a postdoctoral scientist at MIT.

He holds an MD from Harvard Medical School, a PhD in Chemistry and Chemical Biology from Harvard University, a master’s degree in Electrical Engineering and Computer Science from MIT, and a bachelor’s degree from Caltech in Chemistry.

Martin Wildy, CFA

Portfolio Manager

Martin Wildy, CFA, serves as Portfolio Manager of Eventide’s Multi-Asset Income Fund

Prior to joining Eventide in 2015, Mr. Wildy was a Senior Portfolio Manager with Aris Wealth Services, a division of AssetMark, Inc. where he worked since September 2006. Previously, Mr. Wildy was an equity analyst at 1620 Investment Advisors, Inc. where he was responsible for equity research and recommendations primarily within the telecommunication, technology, and regional banking sectors.

Mr. Wildy holds a bachelor’s degree from the Pennsylvania State University in Finance and has held the Chartered Financial Analyst (CFA) designation since 2003. In addition to his role at Eventide, Mr. Wildy is an active volunteer and consultant with the CFA Institute supporting the CFA examination process as well as the CFA Digest publication.

David Barksdale

Chief Financial Officer, Portfolio Manager, Managing Partner

David Barksdale serves as Eventide’s CFO and is a co-Portfolio Manager on the Eventide Gilead Fund. In addition to managing financial operations for Eventide, he is responsible for developing and applying novel analytical tools and strategies in support of Eventide’s portfolio management.

Prior to joining Eventide in 2008, Mr. Barksdale served as a Senior Services Manager with Cadence Design Systems, an information technology company. He holds a bachelor’s degree from Caltech in Engineering & Applied Science.

Research Analysts

Andrew Singer, CFA

Senior Analyst

Andrew Singer serves as Senior Analyst for Eventide. Mr. Singer is responsible for making investment recommendations and monitoring existing portfolio investments by conducting fundamental, financial, and valuation analyses.

Prior to joining Eventide, Mr. Singer held investment analyst positions at Credit Suisse, BlackRock, and John Hancock, where he focused on small- and mid-cap equities across a variety of sectors. He has a bachelor’s degree in Quantitative Economics from Tufts University and an MBA from Babson College. Mr. Singer holds the Chartered Financial Analyst designation and is a member of the Boston Security Analysts Society and CFA Institute.

Agustin Mohedas, PhD

Research Analyst

Agustin Mohedas serves as a Research Analyst for Eventide. He is primarily responsible for evaluating and monitoring new and existing healthcare investment opportunities in the portfolios.

Prior to joining Eventide, Dr. Mohedas was an investment analyst at RA Capital where he focused on evidence-based investing in small- and mid-cap life science equities. Dr. Mohedas holds a BS in Biomedical Engineering from Texas A&M University and a PhD in Medical Engineering Medical Physics from the Harvard-MIT Division of Health Sciences and Technology. In his doctoral research, Agustin developed small molecule compounds to treat fibrodysplasia ossificans progressiva, a rare and devastating genetic disorder.

Anant Goel

Research Analyst

Anant Goel serves as a Research Analyst for Eventide. He is primarily responsible for evaluating and monitoring new and existing investment opportunities in the portfolios.

Mr. Goel has an MBA from the MIT Sloan School of Management, during which time he worked at Adage Capital Management. Prior to MIT, he was an analyst for NewQuest Capital Partners, the leading secondary private equity platform in Asia. He holds a B.Sc. (HONS) from the University of Warwick, UK, in Economics and is a CFA Level III Candidate.

Tianxiang Chen

Computational Equity Analyst

Tianxiang Chen serves as Computational Equity Analyst for Eventide's portfolio management team. In his role, Mr. Chen provides quantitative portfolio analysis, investment strategies implementation, and top down equity research.

Mr. Chen has a Master's Degree in Mathematical Finance from Boston University and a dual Bachelor's Degree in Statistical Mathematics and Computer Science, with an Economics minor from University of Virginia.

Portfolio Operations

Colin Delaney

Director of Portfolio Operations, Product Specialist

Colin Delaney serves as Director of Portfolio Operations and is a Product Specialist for the Advisory Services team at Eventide. In his role in Portfolio Operations, Mr. Delaney works closely with the Fund's Portfolio Managers and the investment team to help implement their investment strategies. In his role as Product Specialist, Mr. Delaney acts as a link between Eventide's investment team and our client Advisors, helping them understand the portfolio's investments and strategies.

Prior to Eventide, Mr. Delaney was a Senior Vice President at Jefferies LLC, where he served as a sales trader and client relations manager. In nearly 15 years at Jefferies, he was able to participate in a broad range of investment activities giving him a deep and wide understanding of the complete investment process. Mr. Delaney has a degree in Economics from St. Lawrence University.

Executive Team

Robin John

Chief Executive Officer, Managing Partner

Robin John is co-founder and Chief Executive Officer of Eventide. Under his leadership, the firm has grown into a leader within the socially responsible and faith-based investment marketplace. Mr. John was named to the “2016 Ten to Watch” list by Wealth Management Magazine. He leads all business development efforts for Eventide and oversees daily operations, including broker-dealer relations, and fund administration.

Prior to Eventide, Mr. John held leadership roles for Bank of New York Mellon where he worked closely with the Global Securities Services team management, Human Resources management, and Business Continuity Team in creating more efficient processes and mitigating cost. He has also served as a business consultant for Grant Thornton where he specialized in Sarbanes-Oxley compliance and SAS 70 accounting standards. He has a degree in Economics from Tufts University.

Connect with Robin on LinkedIn.

Finny Kuruvilla, MD, PhD

Chief Investment Officer, Portfolio Manager, Managing Partner

Finny Kuruvilla serves as the CIO for Eventide Funds, lead Portfolio Manager on the Eventide Gilead Fund, and Portfolio Manager on the Eventide Healthcare & Life Sciences Fund.

Dr. Kuruvilla has a unique background in healthcare, statistics, and investing. Concurrent with Eventide, from 2008 through 2016, he was a Principal at Clarus Ventures, a leading healthcare and life sciences venture capital firm. Prior to joining Eventide, from 2006-2008, Dr. Kuruvilla was a research fellow at the Broad Institute of Harvard and MIT, and from 2005-2008, Dr. Kuruvilla was a clinical fellow at the Brigham and Women’s Hospital and Children’s Hospital Boston and a postdoctoral scientist at MIT.

He holds an MD from Harvard Medical School, a PhD in Chemistry and Chemical Biology from Harvard University, a master’s degree in Electrical Engineering and Computer Science from MIT, and a bachelor’s degree from Caltech in Chemistry.

David Barksdale

Chief Financial Officer, Portfolio Manager, Managing Partner

David Barksdale serves as Eventide’s CFO and is a co-Portfolio Manager on the Eventide Gilead Fund. In addition to managing financial operations for Eventide, he is responsible for developing and applying novel analytical tools and strategies in support of Eventide’s portfolio management.

Prior to joining Eventide in 2008, Mr. Barksdale served as a Senior Services Manager with Cadence Design Systems, an information technology company. He holds a bachelor’s degree from Caltech in Engineering & Applied Science.

Jason Myhre

Director of Marketing & Advisory Services, Managing Partner

Jason Myhre serves as the Director of Marketing and Advisory Services for Eventide. He is responsible for Eventide’s internal support and service to advisory relationships, overseeing Eventide’s Advisory Services team, including the Product Specialist team.

Prior to Eventide, Mr. Myhre worked in internal sales and managed key customer relationships for Altec. He holds a master’s and bachelor’s degree from the University of Florida, and studied architecture at Harvard’s Graduate School of Design.

Peter Luiso

Chief Compliance Officer and General Counsel

Peter Luiso serves Eventide as CCO, managing Eventide’s compliance program.

Prior to joining Eventide in June 2016, Peter held several roles at Fidelity Investments, most recently Deputy CCO of Fidelity’s Strategic Advisers Funds, where he provided regulatory guidance to many of Fidelity’s investment advisers, broker-dealers, and retirement businesses. Before that, Mr Luiso served as a Senior Enforcement Attorney for the U.S. Securities and Exchange Commission and as Trial Counsel for the New York Stock Exchange.

Peter holds a bachelor’s degree in Criminal Justice from Northeastern University in Boston and a J.D. from Georgia State University College of Law in Atlanta.

BJ Cheriakalath

Director of Compliance

BJ Cheriakalath serves as Director of Compliance at Eventide. He works to ensure compliance with applicable regulatory and procedural requirements, including the Funds’ adherence to Prospectus/SAI restrictions.

Prior to joining Eventide, Mr. Cheriakalath served as a supervisor at Bank of New York Mellon’s Corporate Actions department. He has a degree in Economics from Tufts University.

Mutual Funds involve risk including the possible loss of principal. Past performance does not guarantee future results.The Funds’ ethical values screening criteria could cause it to under-perform similar funds that do not have such screening criteria. The Funds can have risk related to option investing. There are special risks associated with investments in foreign companies including exposure to currency fluctuations, less efficient trading markets, political instability and differing auditing and legal standards. Because of ongoing market volatility, the Funds performance may be subject to substantial short-term changes.

The Eventide Gilead Fund & Eventide Healthcare & Life Sciences Fund can invest in smaller-sized companies which may experience higher failure rates than larger companies and they normally have a lower trading volume than larger companies. The Funds can also have risk associated with the biotechnology and pharmaceutical industry in which these companies may be heavily dependent on clinical trials with uncertain outcomes and decisions made by the U.S. Food and Drug Administration. The Funds can invest in private companies. Private investments include various risks including but not limited to lack of liquidity, capital commitment risk, and valuation risk. Private companies may not be financially profitable and have uncertain futures, thus subject to additional risks. Investors in the Gilead Fund should be aware that companies in the technology industries have different risks including but not limited to products becoming obsolete, and entrance of competing products.

Investors in the Eventide Multi-Asset Income Fund should be aware that interest rates are at historic lows and may change at any time based on government policy. In general, the price of a fixed income security falls when interest rates rise. A rise in interest rates may result in volatility and increased redemptions, which in turn could result in the fund being forced to liquidate portfolio securities at disadvantageous prices. Longer-term securities may be more sensitive to changes in interest rates. The intermediate-term bond portion of the Fund’s portfolio may represent 0% to 100% of the Fund’s portfolio with an average duration of between two and eight years.

The Eventide Multi-Asset Income Fund may invest in other funds. If other funds are utilized, such underlying funds are subject to investment advisory and other expenses, which will be indirectly paid by the Fund. As a result, your cost of investing in the Fund will be higher than the cost of investing directly in underlying funds and may be higher than other mutual funds that do not invest in underlying funds. The Fund may invest, directly or indirectly, in “junk bonds.” Such securities are speculative investments that carry greater risks than higher quality debt securities. There are unique risks associated with REITs, MLPs, preferred stocks, convertible bonds, BDCs, and yieldcos that are covered in the Fund's prospectus and SAI. The Fund is a new mutual fund and has a limited history of operations for investors to evaluate.

An investor should consider a fund's investment objectives, risks, charges and expenses carefully before investing or sending money. This and other important information can be found in the prospectus, which can be obtained at www.eventidefunds.com or by calling 1-877-771-EVEN (3836). Please read the prospectus carefully before investing. Eventide Mutual Funds are distributed by Northern Lights Distributors, LLC, Member FINRA, which is not affiliated with Eventide Asset Management, LLC.